Ipamorelin is a short synthetic pentapeptide designed as a selective growth-hormone secretagogue, notable for its compact five-residue backbone and its use of non-natural amino acids. Its small size and carefully chosen residues are precisely what give it the receptor selectivity that distinguishes it from bulkier or less-refined secretagogues.
A designed pentapeptide
Ipamorelin's sequence is conventionally written as Aib-His-D-2-Nal-D-Phe-Lys-NH2, a five-residue chain terminating in a C-terminal amide. Rather than being derived from a natural protein, it was engineered residue by residue, with each position chosen to optimize binding to the ghrelin/GHS receptor — the basis of its mechanism of action. How such non-standard residues fit into an ordered chain is covered in understanding amino acid sequences.
Non-natural residues
Several building blocks are not found in ordinary proteins: aminoisobutyric acid (Aib) constrains the backbone conformation and resists enzymatic cleavage, while D-configured and naphthylalanine residues sharpen receptor selectivity and stability. These deliberate substitutions are the structural reason ipamorelin behaves so cleanly at its target.
The C-terminal amide
Capping the chain with an amide rather than a free carboxyl removes a negative charge and further improves resistance to carboxypeptidases, a small but meaningful contributor to the molecule's stability profile.
Synthesis and finishing
The short length makes solid-phase peptide synthesis efficient and high-yielding; the peptide is assembled on resin, cleaved, purified by preparative chromatography, and then lyophilized (what is lyophilization) into a stable powder for shipping and storage.
Quality confirmation
Purity and identity are read out by HPLC and mass spectrometry, the latter confirming the expected molecular weight including its non-natural residues. See also its discovery and history and the broader research overview.
Protecting-group and stereochemical control
Manufacturing a short sequence is not automatically trivial. Each D-residue and nonstandard aromatic building block must have the correct stereochemistry, and side-chain protecting groups must survive repeated coupling cycles before being removed cleanly during final cleavage. Incomplete coupling can create deletion sequences whose masses differ only modestly from the target, while racemization can yield an isomer with the same elemental composition but altered receptor behavior. Process controls therefore monitor coupling completion, and final characterization uses more than nominal peptide content. The compact sequence reduces the number of assembly steps, but its biological selectivity makes exact residue identity and configuration unusually important.
Product page: Ipamorelin research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.